Literature DB >> 24526754

Magnetic resonance imaging of breast cancer: factors affecting the accuracy of preoperative lesion sizing.

Simone Mennella1, Alessandro Garlaschi2, Francesco Paparo3, Marco Perillo1, Matteo Celenza4, Tiberio Massa2, Gian Andrea Rollandi3, Giacomo Garlaschi1.   

Abstract

BACKGROUND: Accurate preoperative sizing of breast cancer with imaging modalities has a great importance in the surgical planning.
PURPOSE: To assess the influence of tumor size and histology on the accuracy of measurement of cancer local extension by magnetic resonance imaging (MRI).
MATERIAL AND METHODS: One hundred and eighty-six patients with primary breast cancer, for a total of 221 lesions, were included in this retrospective study. Tumors were divided into five histological groups: invasive ductal carcinoma (IDC), IDC with extensive intraductal component (EIC), invasive lobular carcinoma (ILC), ductal carcinoma in situ (DCIS), and "other histology" (mucinous, papillary, medullary, tubular, and apocrine breast cancer). Microscopic measurement of the largest diameter of tumors at pathology was chosen as reference standard and compared with MRI measurement. Concordance was defined as a difference ≤ 5 mm between MRI and pathology.
RESULTS: The mean size of tumors at pathology was 24.8 ± 19.4 mm, while at MRI it was 29.7 ± 20 mm (P < 0.05), with a significant overestimation of MRI. MRI-pathology concordance was found in 98/221 cases (44.3%), while MRI overestimated the size of 81/221 tumors (36.7%). The extent of overestimation was significantly different among the five histological groups (P < 0.05). At multivariate analysis, DCIS histology was the factor more significantly associated with MRI-pathology discordance (P = 0.0005), while the influence of tumor dimension at pathology was less significant (P = 0.0073).
CONCLUSION: DCIS histology is strongly associated with discordance between MRI and pathology sizing of breast cancer. Lesion size can also influence the accuracy of MRI measurements, but to a lesser extent. © The Foundation Acta Radiologica 2014 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav.

Entities:  

Keywords:  MRI; ductal carcinoma in situ; invasive breast cancer; pathology; tumor size

Mesh:

Year:  2014        PMID: 24526754     DOI: 10.1177/0284185114524089

Source DB:  PubMed          Journal:  Acta Radiol        ISSN: 0284-1851            Impact factor:   1.990


  11 in total

1.  Which factors influence MRI-pathology concordance of tumour size measurements in breast cancer?

Authors:  M Rominger; D Berg; T Frauenfelder; A Ramaswamy; N Timmesfeld
Journal:  Eur Radiol       Date:  2015-08-14       Impact factor: 5.315

2.  Diagnostic performance of contrast-enhanced dual-energy spectral mammography (CESM): a retrospective study involving 644 breast lesions.

Authors:  María Del Mar Travieso-Aja; Daniel Maldonado-Saluzzi; Pedro Naranjo-Santana; Claudia Fernández-Ruiz; Wilsa Severino-Rondón; Mario Rodríguez Rodríguez; Víctor Vega Benítez; Octavio Pérez-Luzardo
Journal:  Radiol Med       Date:  2019-06-27       Impact factor: 3.469

3.  Comparison of MRI and US in Tumor Size Evaluation of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy.

Authors:  Onur Taydaş; Gamze Durhan; Meltem Gülsün Akpınar; Figen Başaran Demirkazık
Journal:  Eur J Breast Health       Date:  2019-04-01

4.  Relevance of breast MRI in determining the size and focality of invasive breast cancer treated by mastectomy: a prospective study.

Authors:  Anne-Julie Carin; Sébastien Molière; Victor Gabriele; Massimo Lodi; Nicolas Thiébaut; Karl Neuberger; Carole Mathelin
Journal:  World J Surg Oncol       Date:  2017-07-14       Impact factor: 2.754

5.  The clinical significance of accompanying NME on preoperative MR imaging in breast cancer patients.

Authors:  Hye Mi Gweon; Joon Jeong; Eun Ju Son; Ji Hyun Youk; Jeong-Ah Kim; Kyung Hee Ko
Journal:  PLoS One       Date:  2017-05-30       Impact factor: 3.240

6.  Higher underestimation of tumour size post-neoadjuvant chemotherapy with breast magnetic resonance imaging (MRI)-A concordance comparison cohort analysis.

Authors:  Wen-Pei Wu; Hwa-Koon Wu; Chih-Jung Chen; Chih-Wie Lee; Shou-Tung Chen; Dar-Ren Chen; Chen-Te Chou; Chi Wei Mok; Hung-Wen Lai
Journal:  PLoS One       Date:  2019-10-10       Impact factor: 3.240

7.  Influence of Tumor Subtype, Radiological Sign and Prognostic Factors on Tumor Size Discrepancies Between Digital Breast Tomosynthesis and Final Histology.

Authors:  Alessandro Garlaschi; Massimo Calabrese; Federico Zaottini; Simona Tosto; Marco Gipponi; Paola Baccini; Maurizio Gallo; Alberto Stefano Tagliafico
Journal:  Cureus       Date:  2019-10-31

8.  Diagnostic performance of digital breast tomosynthesis for predicting response to neoadjuvant systemic therapy in breast cancer patients: A comparison with magnetic resonance imaging, ultrasound, and full-field digital mammography.

Authors:  Ryusuke Murakami; Hitomi Tani; Shinichiro Kumita; Nachiko Uchiyama
Journal:  Acta Radiol Open       Date:  2021-12-20

9.  Agreement between dynamic contrast-enhanced magnetic resonance imaging and pathologic tumour size of breast cancer and analysis of the correlation with BI-RADS descriptors.

Authors:  Aysegul Akdogan Gemici; Ercan Inci
Journal:  Pol J Radiol       Date:  2019-12-27

10.  Accuracy of breast MRI in patients receiving neoadjuvant endocrine therapy: comprehensive imaging analysis and correlation with clinical and pathological assessments.

Authors:  Joana Reis; Jonas Christoffer Lindstrøm; Joao Boavida; Kjell-Inge Gjesdal; Daehoon Park; Nazli Bahrami; Manouchehr Seyedzadeh; Woldegabriel A Melles; Torill Sauer; Jürgen Geisler; Jonn Terje Geitung
Journal:  Breast Cancer Res Treat       Date:  2020-08-12       Impact factor: 4.624

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.